Skip to main content
SpringerLink
Log in

Variazioni della densità ossea indotte da trattamento e rischio di frattura vertebrale

  • Published:
L’Endocrinologo Aims and scope

Riassunto

Il recente completamento di trial clinici sull’attività antifrattura degli inibitori del turnover osseo ha sollevato la questione se la variazione osservata nella densità minerale ossea (DMO) spieghi completamente l’efficacia antifrattura.

Per rispondere a questa domanda, è necessario identificare una relazione normativa tra DMO e rischio di fratture vertebrali morfometriche.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Bibliografia

  1. Johnston C.C., Slemenda C.W., Melton L.J. Clinical use of bone densitometry. N. Engl. J. Med. 324: 1105, 1991.

    Article  PubMed  Google Scholar 

  2. Spector T.D., McCloskey E.V., Doyle D.V., Kanis J.A. Prevalence of vertebral fracture in women and the relationship with bone density and symptoms: The Chingford Study. J. Bone Miner. Res. 8: 817, 1993.

    Article  PubMed  CAS  Google Scholar 

  3. Grampp S., Genant H.K., Mathur A., Lang P., Jergas M., Takada M., Gluer C.C., Lu Y., Chavez M. Comparisons of noninvasive bone mineral measurements in assessing age-related loss, fracture discrimination, and diagnostic classification. J. Bone Miner. Res. 12: 697, 1997.

    Article  PubMed  CAS  Google Scholar 

  4. Black D., Cummings S.R., Genant H.K, Nevitt M.C., Palermo L., Browner W. Axial and appendicular bone density predict fractures in older women. J. Bone Miner. Res. 7: 633, 1992.

    Article  PubMed  CAS  Google Scholar 

  5. WHO. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO technical report series no. 843 WHO, Geneva, 1994.

    Google Scholar 

  6. Cummings S.R., Nevitt M.C., Bowner W.S., Stone K., Fox K.M., Ensrud K.E., Cauley J., Black D., Vogt T.M. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N. Engl. J. Med. 332: 767, 1995.

    Article  PubMed  CAS  Google Scholar 

  7. Melton III L.J., Atkinson E.J., O’Fallon W.M., Wahner HW, Riggs B.L. Longterm fracture prediction by bone mineral density assessed at different skeletal sites. J. Bone Miner. Res. 8: 1227, 1993.

    Article  PubMed  Google Scholar 

  8. Cummings S.R., Black D.M., Nevitt M.C., Browner W., Cauley J., Ensrud K.E., Genant H.K., Palermo L., Scott J., Vogt T.M. Bone density at various sites for prediction of hip fractures. The study of Osteoporotic Fractures Research Group. Lancet 341: 72, 1993.

    Article  PubMed  CAS  Google Scholar 

  9. Garnero P., Hausherr E., Chapuy M.C., Marcelli C., Grandjean H., Muller C., Cormier C., Bréart G., Meunier P.J., Delmas P.D. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J. Bone Miner. Res. 11: 1531, 1996.

    Article  PubMed  CAS  Google Scholar 

  10. Adami S., Kenis J.A. Assessment of involutional bone loss: methodological and conceptual problems. J. Bone Miner. Res. 10: 511, 1995.

    Article  PubMed  CAS  Google Scholar 

  11. Riggs B.L., Melton III L.J., O’Fallon W.M. Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone 18: 197S, 1996.

    Article  PubMed  CAS  Google Scholar 

  12. Einhorn T.A. Bone strength: the bottom line. Calcif. Tissue Int. 51: 333, 1992.

    Article  PubMed  CAS  Google Scholar 

  13. Parfitt A.M., Mathews C.H.E., Villaneuva A.R., Kleerekoper M., Frame B., Rao D.S. Relationship between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. J. Clin. Invest. 72: 1396, 1983.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  14. Adami S., Braga V., Squaranti R., Rossini M., Gatti D., Zamberlan N. Bone measurements in asymptomatic primary hyperparathyroidism. Bone 22: 565, 1998.

    Article  PubMed  CAS  Google Scholar 

  15. Wilson R.J., Rao S., Ellis B., Kleerkoper M., Parfitt A.M. Mild asymptomatic primary hyperparathyroidism is a not a risk actor for vertebral fractures. Ann. Intern. Med. 109: 959, 1988.

    Article  PubMed  CAS  Google Scholar 

  16. Adachi J.D., Bensen W.G., Brown J., Hanley D., Hodsman A., Josse R., Kendler D., Lentle B., Olszynski W., SteMarie L., Tenehouse A., Chines A.A. Intermittent etidronate therapy to prevent corticosteroid induced osteoporosis. N. Engl. J. Med. 337: 382, 1997.

    Article  PubMed  CAS  Google Scholar 

  17. Saag K.G., Emkey R., Schnitzer T.J., Brown J.P., Hawkins F., Goemaere S., Thamsborg G., Liberman U.A., Delmas P.D., Malice M.P., Czachur M., Daifotis A. Alendronate for the prevention and treatment of glucocorticoid induced osteoporois. N. Engl. J. Med. 339: 292, 1998.

    Article  PubMed  CAS  Google Scholar 

  18. Reid D., Devogelar J.P., Hughes R., Laan R., Adami S., SaccoGibson N., Wenderoth D. Risedronate is effective and well tolerated in treating corticosteroidinduced osteoporosis. J. Bone Miner. Res. 12: P23, 1998.

    Google Scholar 

  19. Cooper C., Atkinson E.J., O’Fallon W.M., Melton III L.J. Incidence of clinically diagnosed vertebral fractures: a populationbased study in Rochester, Minnesota, 1985–1989. J. Bone Miner. Res. 7: 221, 1992.

    Article  PubMed  CAS  Google Scholar 

  20. Cooper C., Shah S., Hand D.J., Adams J., Compston J., Davie M., Woolf A. Screening for osteoporosis using individuai risk factors. Osteoporos. Int. 2: 48, 1991.

    Article  PubMed  CAS  Google Scholar 

  21. Looker A.C., Wahner H.W., Dunn W.L., Calvo M.S., Harris T.B., Heyse S.P., Johnston C.C., Lindsay Jr R. Proximal femur bone mineral levels of US adults. Osteoporos. Int. 5: 389, 1995.

    Article  PubMed  CAS  Google Scholar 

  22. Melton III L.J., Lane A.W., Cooper C., Eastell R., O’Fallon W.M., Riggs B.L. Prevalence and incidence of vertebral deformities. Osteoporos. Int. 3: 113, 1993.

    Article  PubMed  Google Scholar 

  23. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., Bauer D.C., Genant H.K., Haskell W.L., Marcus R., Ott S.M., Torner J.C., Quandt S.A., Reiss T.F., Ensrud K.E., for the Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348: 1535, 1996.

    Article  PubMed  CAS  Google Scholar 

  24. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett Connor E., Musliner T.A., Palermo L., Prineas R., Rubin S.M., Scott J.C., Vogt T., Wallage R., Yates A.J., La Croix A.Z., for the Fracture Intervention Trial Research Group. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280: 2077, 1998.

    Article  PubMed  CAS  Google Scholar 

  25. Delmas P.D. Raloxifene reduces the risk of vertebral fracture and improves lipid profiles of postmenopausal women after 3 years. Calcif. Tissue Int. 64(Suppl. 1): S6, 1999.

    Google Scholar 

  26. Ross P.D., Genant H.K., Davis J.W., Miller P.D., Wasnich R.D. Predicting vertebral fracture incidence from prevalent fractures and bone density among nonblack, osteoporotic women. Osteoporos. Int. 3: 120, 1993.

    Article  PubMed  CAS  Google Scholar 

  27. Chevalley T., Rizzoli R., Nydegger V., Slosman D., Rapin C.H., Michel J.P., Vasey H., Bonjour J.P. Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin D replete elderly patients. Osteoporos. Int. 4: 245, 1994.

    Article  PubMed  CAS  Google Scholar 

  28. Dawson Hughes B., Harris S.S., Krall E.A., Dallal G.E. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N. Engl. J. Med. 337: 670, 1997.

    Article  PubMed  CAS  Google Scholar 

  29. Kleerekoper M., Mendlovic D.B. Sodium fluoride therapy of postmenopausal osteoporosis. Endocr. Rev. 14: 312, 1993.

    PubMed  CAS  Google Scholar 

  30. Pak C.Y.C., Zerwekh J.E., Antich P.P., Bell N.H., Singer F.R. Slowrelease sodium fluoride in osteoporosis. Osteoporos. Int. 11: 561, 1996.

    CAS  Google Scholar 

  31. Riggs B.L., Hodgson S.F., O’Fallon W.M., et al. Effect of fluoride treatment on fracture rate in postmenopausal women with osteoporosis. N. Engl. J. Med. 322: 802, 1990.

    Article  PubMed  CAS  Google Scholar 

  32. Meunier P.J., Sebert J.L, Reginster J.Y., Briancon D., Appelboom T., Netter P., Loeb G., Rouillon A., Barry S., Evreux J.C., Avouac B., Marchandise X., the FAVO Study Group. Fluoride salts are no better at preventing new vertebral fractures than calcium vitamin D in postmenopausal osteoporosis: The FAVO Study. Osteoporos. Int. 8: 4, 1998.

    Article  PubMed  CAS  Google Scholar 

  33. Liberman U.A., Weiss S.R., Bröll J., Minne H.W., Quan H., Bell N.H., Rodriguez Portales J., Downs R.W. Jr., Dequeker J., Favus M., Seeman E., Recker R., Capizzi T., Santora A.C., Lombardi A., Shah R.V., Hirsch L.J., Karpf D. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N. Engl. J. Med. 333: 1437, 1995.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Riabilitazione Reumatologica, Ospedale di Valeggio, Università di Verona, Verona, Italia

    S. Adami, O. Viapiana & F. Corallo

Authors
  1. S. Adami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Viapiana
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Corallo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adami, S., Viapiana, O. & Corallo, F. Variazioni della densità ossea indotte da trattamento e rischio di frattura vertebrale. L’Endocrinologo 1 (Suppl 1), 1–7 (2000). https://doi.org/10.1007/BF03344361

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03344361

Search

Navigation